Long-term changes in body weight and serum cholesterol in heart transplant recipients

Clin Transplant. 2022 Dec;36(12):e14819. doi: 10.1111/ctr.14819. Epub 2022 Sep 25.

Abstract

Introduction: Long-term changes in weight and blood lipids beyond 12 months after heart transplantation are largely unknown. We quantified changes in weight, body mass index (BMI), blood cholesterol, and triglycerides in heart transplant recipients (HTRs) during the 36 months after transplantation, and we assessed the influence of statin therapy on these outcomes.

Methods: Retrospective cohort study of adult HTRs, transplanted 1990-2017, in Queensland, Australia. From each patient's medical charts, we extracted weight, total cholesterol, triglycerides, and statin therapy at four time-points: time of transplant (baseline), and 12-, 24-, 36-month post-transplant. Changes in weight and blood lipids were assessed according to baseline BMI.

Results: Among 316 HTRs, 236 (median age 52 years, 83% males) with available information were included. During the 36 months post-transplant, all patients gained weight (83.5-90.5 kg; p < .001), especially those with baseline BMI < 25.0 km/m2 (67.9-76.2 kg; p < .001). Mean blood cholesterol (4.60-4.90 mmol/L; p = .004) and mean blood triglycerides (1.79-2.18 mmol/L; p = .006) also increased significantly in all patients, particularly in those with baseline BMI ≥ 25.0 km/m2 but the differences were not significant (total cholesterol 4.42-5.13 mmol/L; triglycerides 1.76-2.47 mmol/L). Total cholesterol was highest in patients not taking statins, and levels differed significantly (p = .010) according to statin dosing changes during the 36 months post-transplant.

Conclusion: Patients demonstrate significant rises in weight and blood lipids in the 36 months after heart transplantation.

Keywords: blood lipids; body mass index; heart transplantation; weight gain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Body Weight
  • Cholesterol
  • Female
  • Heart Transplantation* / adverse effects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Lipids
  • Male
  • Middle Aged
  • Retrospective Studies
  • Triglycerides

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Triglycerides
  • Lipids
  • Cholesterol